Targeted delivery and controlled release of polymeric nanomedicines for tumor therapy
Fundamental Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Bacterial Systems as a Precision Delivery Platform of Therapeutic Peptides for Cancer Therapy
Polymer science & technology.,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 5, 2025
Язык: Английский
Advances in Engineered Bacteria for Cancer Therapy
Precision medicine and engineering.,
Год журнала:
2025,
Номер
unknown, С. 100017 - 100017
Опубликована: Фев. 1, 2025
Язык: Английский
Thermal-responsive ultrasound activatable in situ production of therapeutics for real-time imaging and targeted tumor therapy
Theranostics,
Год журнала:
2025,
Номер
15(9), С. 4212 - 4228
Опубликована: Март 18, 2025
Rationale:
Engineered
bacteria
with
tumor-targeting
capabilities
and
genetic
modification
potential
have
emerged
as
promising
vectors
for
targeted
tumor
therapy
through
the
effective
production
release
of
therapeutic
molecules.
Controlled
gene
expression
real-time
monitoring
protein
in
tumors
are
great
significance
optimizing
engineered
well
anti-tumor
effects.
Methods:
We
constructed
E.
coli
MG1655
cells
using
recombinant
thermal
plasmid
pBV220
carrying
optical
imaging
reporter
miRFP720
Cytolysin
A,
which
could
be
controlled
expressed
synchronously
by
effect
produced
focused
ultrasound.
The
concentrations
A
after
ultrasound
irradiation
were
detected
vitro
vivo
western
blot
analysis
enzyme-linked
immunosorbent
assay
(ELISA)
analysis.
immune
cell
infiltration
rate
inflammation
factors
treatment
flow
cytometry
ELISA
efficacy
alone
or
combined
anti-Programmed
death
1
ligand
(aPD-L1)
immunotherapy
evaluated
on
subcutaneous
models
orthotopic
glioblastoma
models.
Results:
Upon
ultrasound-controlled
activation,
level
molecule
probe
enhanced.
Importantly,
monitored
non-invasively
signal
intensity
miRFP720,
provided
guidance
optimized
ultrasound-mediated
situ.
Furthermore,
not
only
exerted
potent
effects
but
also
induced
immunogenic
death,
enhancing
efficiency
aPD-L1
deep
site
treatment.
Conclusion:
In
this
study,
a
guided
activatable
mode
was
established.
Utilizing
ultrasound,
A-miRFP720
can
concurrently
express
mode,
realized
enhanced
local
immunotherapy.
Язык: Английский
Living Therapeutics: Precision Diagnosis and Therapy with Engineered Bacteria
Biomaterials,
Год журнала:
2025,
Номер
321, С. 123342 - 123342
Опубликована: Апрель 15, 2025
Язык: Английский
Engineered Bacteria: Strategies and Applications in Cancer Immunotherapy
Fundamental Research,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 1, 2024
Язык: Английский
Bacterial Outer Membrane Vesicle (OMV)-Encapsulated TiO2 Nanoparticles: A Dual-Action Strategy for Enhanced Radiotherapy and Immunomodulation in Oral Cancer Treatment
Nanomaterials,
Год журнала:
2024,
Номер
14(24), С. 2045 - 2045
Опубликована: Дек. 20, 2024
Oral
squamous-cell
carcinoma
(OSCC)
poses
significant
treatment
challenges
due
to
its
high
recurrence
rates
and
the
limitations
of
current
therapies.
Titanium
dioxide
(TiO2)
nanoparticles
are
promising
radiosensitizers,
while
bacterial
outer
membrane
vesicles
(OMVs)
known
for
their
immunomodulatory
properties.
This
study
investigates
potential
OMV-encapsulated
TiO2
(TiO2@OMV)
combine
these
effects
improved
OSCC
treatment.
were
synthesized
using
a
hydrothermal
method
encapsulated
within
OMVs
derived
from
Escherichia
coli.
The
TiO2@OMV
carriers
evaluated
ability
enhance
radiosensitivity
stimulate
immune
responses
in
cell
lines.
Reactive
oxygen
species
(ROS)
production,
macrophage
recruitment,
selective
cytotoxicity
toward
cancer
cells
assessed.
demonstrated
radiosensitization
activation
compared
unencapsulated
nanoparticles.
system
selectively
induced
cells,
sparing
normal
enhanced
ROS
generation
macrophage-mediated
antitumor
responses.
highlights
as
dual-action
therapeutic
platform
that
synergizes
radiotherapy
immunomodulation,
offering
targeted
effective
strategy
approach
could
improve
outcomes
reduce
adverse
associated
with
conventional
Язык: Английский
Application of Invasive Bacteria for the Delivery of Anti-Cancer Therapeutics
Therapeutics,
Год журнала:
2024,
Номер
1(2), С. 124 - 141
Опубликована: Дек. 20, 2024
Bacterial
vectors
for
biomolecule
delivery
to
targeted
organelles,
facilitating
temporary
or
continuous
protein
production,
have
emerged
as
a
promising
approach
treating
acquired
and
inherited
diseases.
This
method
offers
selective
cancer
eradication
targeting
strategy
with
minimal
side
effects.
provide
an
alternative
viral
gene
delivery,
given
their
capacity
deliver
large
genetic
materials
while
inducing
immunogenicity
cytotoxicity.
Bacteria
such
Bifidobacterium,
Salmonella,
Clostridium,
Streptococcus
demonstrated
potential
tumor-targeted
serve
oncolytic
bacteria.
These
also
been
used
transfer
amplify
genes
encoding
biomolecules
pro-drug-converting
enzymes,
toxins,
angiogenesis
inhibitors,
cytokines.
The
microenvironment
of
necrotic
tumors
unique
opportunity
therapy
the
non-pathogenic
anaerobic
bacterium.
For
example,
Clostridium
sporogenes
can
germinate
selectively
in
regions
upon
injection
endospores,
which
helps
enhance
specificity
sporogenes,
resulting
tumor-specific
colonization.
Also,
E.
coli
Salmonella
sp.
be
capacitated
hypoxic
sensing
promotor
into
core
region
solid
tumors.
uniqueness
tumor
microenvironment,
including
hypoxia,
immunosuppression,
metabolite
deficiency
enrichment,
necrosis,
enables
bacteria
tumor.
Combining
traditional
bacterial
will
significantly
complement
cover
limitations
other
treatments.
review
provides
overview
use
vector
therapy,
discussing
strategies
maximize
efficiency
address
challenges.
In
this
review,
we
discuss
anti-cancer
therapeutics
focusing
on
therapeutic
strategies.
We
highlight
complementary
therapies
mechanism
immunotherapy
perspectives
future
use.
Язык: Английский